FRLN

Freeline Therapeutics Holdings plc (FRLN) | Rumor.io

Freeline Therapeutics Holdings

FRLN

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about FRLN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% new

Oct 5

Freeline Therapeutics Holdings plc is developing an enzyme replacement therapy for Gaucher disease and GBA1-linked Parkinson's disease.
The company's longer-acting GCase variant has shown potential in treating GBA1-linked Parkinson's disease, a condition affecting 5-15% of Parkinson's patients.
Analysts have a 82% buy consensus on Freeline Therapeutics Holdings plc, indicating high confidence in the company's prospects.

Generated by AI

Sentiment

Of the messages about FRLN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100%	100%
Bearish	0%	0%	0%	0%

Bullish· Oct 4

Freeline Therapeutics' stock has risen 44.88% after the company reported positive results from initial clinical data, indicating potential for a novel gene therapy candidate.
HC Wainwright & Co. has reiterated a Buy rating on Freeline Therapeutics with a $15 price target.
The company's robust increases of up to 700-fold in plasma GCase enzyme activity in treated patients demonstrate significant potential for its gene therapy candidate.

Bearish· Oct 4

The asset has a limited cash runway and financial woes, making it vulnerable to short sellers and bears.
The stock has a tiny float, which can lead to significant price movements and potential losses for investors.
The company's recent performance has been disappointing, with the stock dropping more than expected after a positive result, and some investors are now predicting a price drop to $4.

Generated by AI

Topics

Of the messages about FRLN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Analysts· May 4

Freeline Therapeutics Holdings plc's stock performance is not directly discussed, but H.C. Wainwright analyst Patrick Trucchio is mentioned as covering the company.
Trucchio is ranked 0 stars on TipRanks.com with an average return of -24.8% and a 22.8% success rate.
Trucchio has a focus on Healthcare sector stocks, including Freeline Therapeutics Holdings, Arrowhead Pharmaceuticals, and Milestone Pharmaceuticals.

Announcements· Oct 4

Freeline Therapeutics Holdings plc (FRLN) reported positive initial clinical data from the first cohort of its Phase 1/2 GALILEO-1 trial of FLT201, its novel gene therapy candidate, in Gaucher disease.
The data showed that a single infusion of FLT201 led to several hundred-fold increases in enzyme activity in the first two patients treated, indicating potential efficacy in treating Gaucher disease.
The positive data led to a significant increase in FRLN's stock price, with shares rising by as much as 47.1% in pre-market trading.

Technical Analysis· Oct 4

$FRLN has broken a trend line and may be due for a reversal.
$FRLN has a history of gaps closing below the opening price, with an average 7% change from open to high.
$FRLN is currently defending key levels, including $5 and $4.5, and may be setting up for a squeeze.

Generated by AI

Community

Of the messages about FRLN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	0%
Newcomers	100%	100%	100%	100%

Regulars· Oct 4

FLT201, Freeline Therapeutics Holdings' adeno-associated virus (AAV) gene therapy candidate, has shown positive initial clinical data in the Phase 1/2 GALILEO-1 trial for Gaucher disease, with several hundred-fold increases in GCase activity and normalization of GCase activity in leukocytes.
Freeline Therapeutics Holdings reported positive initial safety, tolerability, and enzyme activity data from the ongoing Phase 1/2 GALILEO-1 trial evaluating FLT201, with no serious adverse events observed.
The company's American Depositary Shares have seen high trading volume, with over 1.2 million shares traded on the day, exceeding the float of 1.1 million shares, and the stock has popped up 80% since the previous day's close.

Newcomers· Oct 4

Freeline Therapeutics has reported positive initial clinical data from its Phase 1/2 trial of FLT201, a gene therapy candidate for Gaucher disease.
The company's stock has shown a trend of gaps closing below the opening price, with an average percentage change from open to high of the day at 7%.
Freeline Therapeutics has been identified as a potential winner, with delayed data proving to be positive, and the company's stock price increasing from $4 to $7 in a short period of time.

Generated by AI

Also Discussed

Investors talking about FRLN also mention

#	Name	Attention
1	ACHL - Achilles Therapeutics plc	——
2	PRF Technologies Ltd.PRFX	0%+0
3	ImageneBio, Inc.IKNA	0%0
4	Eloxx Pharmaceuticals, Inc. Common StockELOX	0%0
5	Autolus Therapeutics plc ADRAUTL	0%+0
6	Ensysce Biosciences, Inc. Common StockENSC	0%0
7	Amaze Holdings, Inc.VINE	0%new
8	MEOA - Minority Equality Opportunities Acquisition Inc.	——
9	AHI - Advanced Health Intelligence Ltd	——
10	Praxis Precision Medicines, Inc.PRAX	0%0